CP-154526

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H32N4
Molecular Weight	364.527
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCN(CC)C1=NC(C)=NC2=C1C(C)=CN2C3=C(C)C=C(C)C=C3C

InChI

InChIKey=FHQYJZCJRZHINA-UHFFFAOYSA-N

InChI=1S/C23H32N4/c1-8-10-11-26(9-2)22-20-18(6)14-27(23(20)25-19(7)24-22)21-16(4)12-15(3)13-17(21)5/h12-14H,8-11H2,1-7H3

HIDE SMILES / InChI

Molecular Formula	C23H32N4
Molecular Weight	364.527
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9171885
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/10367986 | http://adisinsight.springer.com/drugs/800007484 | https://www.ncbi.nlm.nih.gov/pubmed/18591672

CP 154526 hydrochloride is a selective, non-peptide corticotropin releasing hormone receptor 1 (CRF1) antagonist. CP 154526 readily penetrates the CNS following peripheral administration. In the clinic, CP-154,526 may have important therapeutic utility in treating depression and anxiety as well as other diseases where excessive stimulation of CRF receptors contributes to pathology. The CRF1 receptor antagonist CP-154,526 attenuated the acquisition and prevented the expression of EtOH-induced psychomotor sensitization.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Corticotropin releasing factor receptor 1 8 Target ID: CHEMBL1800 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8816826	Antagonist 2849		2.7 nM [Ki]
Corticotropin releasing factor receptor 2 1 Target ID: CHEMBL4069 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8816826	Antagonist 2849		10.0 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Anxiety 275 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8874139 https://www.ncbi.nlm.nih.gov/pubmed/9171885 https://www.ncbi.nlm.nih.gov/pubmed/9694527	Primary	Preclinical	Unknown Approved Use Unknown
Depression 240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10367986 https://www.ncbi.nlm.nih.gov/pubmed/9171885	Primary	Preclinical	Unknown Approved Use Unknown
Fever 23 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8874139	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist.	1997-05-23	9171885
Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.	1997-03-26	9105872
CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.	1996-09-17	8816826
A non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity.	1996-08-08	8874139

Patents

Sample Use Guides

In Vivo Use Guide

30 mg/kg

Route of Administration: Intraperitoneal

In Vitro Use Guide

CP 154526 completely blocked the activation of adenylate cyclase caused by 100 nM oCRF with an apparent Ki of 3.7 nM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:31:17 GMT 2025` Edited by `admin` on `Mon Mar 31 19:31:17 GMT 2025`
Record UNII	9A549FB00R
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CP-154,526

Preferred Name

English

CP-154526

Common Name

English

7H-PYRROLO(2,3-D)PYRIMIDIN-4-AMINE, N-BUTYL-N-ETHYL-2,5-DIMETHYL-7-(2,4,6-TRIMETHYLPHENYL)-

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID201027582